{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T02:54:36Z","timestamp":1788317676392,"version":"build-2803163510"},"reference-count":82,"publisher":"IMR Press","issue":"7","license":[{"start":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T00:00:00Z","timestamp":1751846400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Front. Biosci. (Landmark Ed)"],"abstract":"<jats:p>Alpha-synuclein (\u03b1-syn) has long been identified as the etiologic agent of multiple neurodegenerative diseases, the most common and well-known of which are Parkinson\u2019s disease (PD) and Lewy body dementia (LBD). While it is known that the pathophysiology of these synucleinopathies involves aggregation of improperly-folded \u03b1-syn, the mechanisms leading to its accumulation have not been fully identified. However, multiple pathways have been proposed, any or all of which may contribute to synucleinopathies. The role of \u03b1-syn in normal homeostasis and in other organ systems, especially the hematopoietic system, has been reported recently. Research within the last decade has shown that \u03b1-syn plays many vital and conserved roles in the cell biology of various organ systems, such as packaging of cell products, exocytosis, membrane stabilization, and more. This protein has been recognized as an essential factor in normal hematopoietic and immune systems function, and its deficiency leads to an abnormal phenotype, in hematopoietic and immune cell lineages. Similar phenotypes in synucleinopathies not only emphasize the conserved nature of the synuclein family but suggest a bimodal pathophysiology in which aggregated \u03b1-syn leads to cellular toxicity while causing derangement of systems that require it. Research into specific molecular mechanisms and potential treatments may provide further understanding of neurodegenerative diseases as well as lead to novel therapies. However, elucidation of the systemic roles of \u03b1-syn in addition to its toxicity in excess is essential to prevent treatment-induced deprivation, which paradoxically harms the patient. Here, we address recent advances in systemic synucleinopathies and putative interconnectedness of these compartments. While previous studies and reviews have focused on the mechanisms of \u03b1-syn synthesis, transport, and aggregation within systems, this review focuses on the potential inter-systemic nature of synucleinopathies and their possible synergistic origins.<\/jats:p>","DOI":"10.31083\/fbl27178","type":"journal-article","created":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T06:16:39Z","timestamp":1754460999000},"source":"Crossref","is-referenced-by-count":5,"title":["Alpha-Synuclein Dysregulation in Systemic Pathophysiology of Synucleinopathies"],"prefix":"10.31083","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6500-7316","authenticated-orcid":true,"given":"Hallie H.","family":"Dolin","sequence":"first","affiliation":[{"name":"Department of Pathology, University Hospitals Cleveland Medical Center and Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4421-9787","authenticated-orcid":true,"given":"Bowen","family":"Zhou","sequence":"first","affiliation":[{"name":"Department of Pathology, University Hospitals Cleveland Medical Center and Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5424-5519","authenticated-orcid":true,"given":"Robert W.","family":"Maitta","sequence":"first","affiliation":[{"name":"Department of Pathology, University Hospitals Cleveland Medical Center and Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"16242","published-online":{"date-parts":[[2025,7,7]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Burr\u00e9 J, Sharma M, S\u00fcdhof TC. Cell Biology and Pathophysiology of \u03b1-Synuclein. Cold Spring Harbor Perspectives in Medicine. 2018; 8: a024091.","DOI":"10.1101\/cshperspect.a024091"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Yang Y, Zhang Z. \u03b1-Synuclein pathology from the body to the brain: so many seeds so close to the central soil. Neural Regeneration Research. 2024; 19: 1463\u20131472.","DOI":"10.4103\/1673-5374.387967"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Smith AN, Joshi S, Chanzu H, Alfar HR, Shravani Prakhya K, Whiteheart SW. \u03b1-Synuclein is the major platelet isoform but is dispensable for activation, secretion, and thrombosis. Platelets. 2023; 34: 2267147.","DOI":"10.1080\/09537104.2023.2267147"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Pei Y, Maitta RW. Alpha synuclein in hematopoiesis and immunity. Heliyon. 2019; 5: e02590.","DOI":"10.1016\/j.heliyon.2019.e02590"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Nakai M, Fujita M, Waragai M, Sugama S, Wei J, Akatsu H, et al. Expression of alpha-synuclein, a presynaptic protein implicated in Parkinson\u2019s disease, in erythropoietic lineage. Biochemical and Biophysical Research Communications. 2007; 358: 104\u2013110.","DOI":"10.1016\/j.bbrc.2007.04.108"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Br\u00e1s IC, Dominguez-Meijide A, Gerhardt E, Koss D, L\u00e1zaro DF, Santos PI, et al. Synucleinopathies: Where we are and where we need to go. Journal of Neurochemistry. 2020; 153: 433\u2013454.","DOI":"10.1111\/jnc.14965"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Stefaniuk CM, Hong H, Harding CV, Maitta RW. \u03b1-Synuclein concentration increases over time in plasma supernatant of single donor platelets. European Journal of Haematology. 2018;  https:\/\/doi.org\/","DOI":"10.1111\/ejh.13152"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Stefaniuk CM, Schlegelmilch J, Meyerson HJ, Harding CV, Maitta RW. Initial assessment of \u03b1-synuclein structure in platelets. Journal of Thrombosis and Thrombolysis. 2022; 53: 950\u2013953.","DOI":"10.1007\/s11239-021-02607-z"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Barbour R, Kling K, Anderson JP, Banducci K, Cole T, Diep L, et al. Red blood cells are the major source of alpha-synuclein in blood. Neuro-degenerative Diseases. 2008; 5: 55\u201359.","DOI":"10.1159\/000112832"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Shameli A, Xiao W, Zheng Y, Shyu S, Sumodi J, Meyerson HJ, et al. A critical role for alpha-synuclein in development and function of T lymphocytes. Immunobiology. 2016; 221: 333\u2013340.","DOI":"10.1016\/j.imbio.2015.10.002"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Xiao W, Shameli A, Harding CV, Meyerson HJ, Maitta RW. Late stages of hematopoiesis and B cell lymphopoiesis are regulated by \u03b1-synuclein, a key player in Parkinson\u2019s disease. Immunobiology. 2014; 219: 836\u2013844.","DOI":"10.1016\/j.imbio.2014.07.014"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Williams GP, Schonhoff AM, Jurkuvenaite A, Gallups NJ, Standaert DG, Harms AS. CD4 T cells mediate brain inflammation and neurodegeneration in a mouse model of Parkinson\u2019s disease. Brain: a Journal of Neurology. 2021; 144: 2047\u20132059.","DOI":"10.1093\/brain\/awab103"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Espay AJ, Lees AJ. Loss of monomeric alpha-synuclein (synucleinopenia) and the origin of Parkinson\u2019s disease. Parkinsonism & Related Disorders. 2024; 122: 106077.","DOI":"10.1016\/j.parkreldis.2024.106077"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Lei Q, Wu T, Wu J, Hu X, Guan Y, Wang Y, et al. Roles of \u03b1 synuclein in gastrointestinal microbiome dysbiosis related Parkinson\u2019s disease progression (Review). Molecular Medicine Reports. 2021; 24: 734.","DOI":"10.3892\/mmr.2021.12374"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"George JM. The synucleins. Genome Biology. 2002; 3: REVIEWS3002.","DOI":"10.1186\/gb-2001-3-1-reviews3002"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Liu C, Zhao Y, Xi H, Jiang J, Yu Y, Dong W. The Membrane Interaction of Alpha-Synuclein. Frontiers in Cellular Neuroscience. 2021; 15: 633727.","DOI":"10.3389\/fncel.2021.633727"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Lashuel HA, Overk CR, Oueslati A, Masliah E. The many faces of \u03b1-synuclein: from structure and toxicity to therapeutic target. Nature Reviews. Neuroscience. 2013; 14: 38\u201348.","DOI":"10.1038\/nrn3406"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Br\u00e1s IC, Xylaki M, Outeiro TF. Mechanisms of alpha-synuclein toxicity: An update and outlook. Progress in Brain Research. 2020; 252: 91\u2013129.","DOI":"10.1016\/bs.pbr.2019.10.005"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Forloni G. Alpha Synuclein: Neurodegeneration and Inflammation. International Journal of Molecular Sciences. 2023; 24: 5914.","DOI":"10.3390\/ijms24065914"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Thorne NJ, Tumbarello DA. The relationship of alpha-synuclein to mitochondrial dynamics and quality control. Frontiers in Molecular Neuroscience. 2022; 15: 947191.","DOI":"10.3389\/fnmol.2022.947191"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Longhena F, Faustini G, Brembati V, Pizzi M, Bellucci A. The good and bad of therapeutic strategies that directly target \u03b1-synuclein. IUBMB Life. 2020; 72: 590\u2013600.","DOI":"10.1002\/iub.2194"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Funato K, Abe T, Kurita R, Watanabe Y, Nakamura Y, Miyata S, et al. Identification of characteristic proteins at late-stage erythroid differentiation in vitro. Human Cell. 2021; 34: 745\u2013749.","DOI":"10.1007\/s13577-021-00503-5"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Araki K, Sugawara K, Hayakawa EH, Ubukawa K, Kobayashi I, Wakui H, et al. The localization of \u03b1-synuclein in the process of differentiation of human erythroid cells. International Journal of Hematology. 2018; 108: 130\u2013138.","DOI":"10.1007\/s12185-018-2457-8"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Park SM, Jung HY, Kim HO, Rhim H, Paik SR, Chung KC, et al. Evidence that alpha-synuclein functions as a negative regulator of Ca(++)-dependent alpha-granule release from human platelets. Blood. 2002; 100: 2506\u20132514.","DOI":"10.1182\/blood.V100.7.2506"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Maitta RW, Wolgast LR, Wang Q, Zhang H, Bhattacharyya P, Gong JZ, et al. Alpha- and beta-synucleins are new diagnostic tools for acute erythroid leukemia and acute megakaryoblastic leukemia. American Journal of Hematology. 2011; 86: 230\u2013234.","DOI":"10.1002\/ajh.21932"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Reheman A, Tasneem S, Ni H, Hayward CPM. Mice with deleted multimerin 1 and alpha-synuclein genes have impaired platelet adhesion and impaired thrombus formation that is corrected by multimerin 1. Thrombosis Research. 2010; 125: e177\u201383.","DOI":"10.1016\/j.thromres.2010.01.009"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Alam MM, Yang D, Li XQ, Liu J, Back TC, Trivett A, et al. Alpha synuclein, the culprit in Parkinson disease, is required for normal immune function. Cell Reports. 2022; 38: 110090.","DOI":"10.1016\/j.celrep.2021.110090"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Tashkandi H, Shameli A, Harding CV, Maitta RW. Ultrastructural changes in peripheral blood leukocytes in \u03b1-synuclein knockout mice. Blood Cells, Molecules & Diseases. 2018; 73: 33\u201337.","DOI":"10.1016\/j.bcmd.2018.09.001"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"Von Coelln R, Thomas B, Savitt JM, Lim KL, Sasaki M, Hess EJ, et al. Loss of locus coeruleus neurons and reduced startle in parkin null mice. Proceedings of the National Academy of Sciences of the United States of America. 2004; 101: 10744\u201310749.","DOI":"10.1073\/pnas.0401297101"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"Burr\u00e9 J, Sharma M, S\u00fcdhof TC. \u03b1-Synuclein assembles into higher-order multimers upon membrane binding to promote SNARE complex formation. Proceedings of the National Academy of Sciences of the United States of America. 2014; 111: E4274\u201383.","DOI":"10.1073\/pnas.1416598111"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"Casini A, Mancinelli R, Mammola CL, Pannarale L, Chirletti P, Onori P, et al. Distribution of \u03b1-synuclein in normal human jejunum and its relations with the chemosensory and neuroendocrine system. European Journal of Histochemistry: EJH. 2021; 65: 3310.","DOI":"10.4081\/ejh.2021.3310"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"Bu LL, Huang KX, Zheng DZ, Lin DY, Chen Y, Jing XN, et al. Alpha-Synuclein Accumulation and Its Phosphorylation in the Enteric Nervous System of Patients Without Neurodegeneration: An Explorative Study. Frontiers in Aging Neuroscience. 2020; 12: 575481.","DOI":"10.3389\/fnagi.2020.575481"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"B\u00f6ttner M, Zorenkov D, Hellwig I, Barrenschee M, Harde J, Fricke T, et al. Expression pattern and localization of alpha-synuclein in the human enteric nervous system. Neurobiology of Disease. 2012; 48: 474\u2013480.","DOI":"10.1016\/j.nbd.2012.07.018"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"Labrie V, Brundin P. Alpha-Synuclein to the Rescue: Immune Cell Recruitment by Alpha-Synuclein during Gastrointestinal Infection. Journal of Innate Immunity. 2017; 9: 437\u2013440.","DOI":"10.1159\/000479653"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"Grathwohl S, Quansah E, Maroof N, Steiner JA, Spycher L, Benmansour F, et al. Specific immune modulation of experimental colitis drives enteric alpha-synuclein accumulation and triggers age-related Parkinson-like brain pathology. Free Neuropathology. 2021; 2: 2\u201313.","DOI":"10.17879\/freeneuropathology-2021-3326"},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"Swaminathan M, Fung C, Finkelstein DI, Bornstein JC, Foong JPP. \u03b1-Synuclein Regulates Development and Function of Cholinergic Enteric Neurons in the Mouse Colon. Neuroscience. 2019; 423: 76\u201385.","DOI":"10.1016\/j.neuroscience.2019.10.029"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"Benvenuti L, Di Salvo C, Bellini G, Seguella L, Rettura F, Esposito G, et al. Gut-directed therapy in Parkinson\u2019s disease. Frontiers in Pharmacology. 2024; 15: 1407925.","DOI":"10.3389\/fphar.2024.1407925"},{"key":"ref38","doi-asserted-by":"publisher","unstructured":"Panaitescu P\u0218, R\u0103zniceanu V, Mocrei-Rebrean \u0218M, Neculicioiu VS, Drago\u0219 HM, Costache C, et al. The Effect of Gut Microbiota-Targeted Interventions on Neuroinflammation and Motor Function in Parkinson\u2019s Disease Animal Models-A Systematic Review. Current Issues in Molecular Biology. 2024; 46: 3946\u20133974.","DOI":"10.3390\/cimb46050244"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"Wijesekara N, Ahrens R, Wu L, Langman T, Tandon A, Fraser PE. \u03b1-Synuclein Regulates Peripheral Insulin Secretion and Glucose Transport. Frontiers in Aging Neuroscience. 2021; 13: 665348.","DOI":"10.3389\/fnagi.2021.665348"},{"key":"ref40","doi-asserted-by":"publisher","unstructured":"Jim\u00e9nez-Jim\u00e9nez FJ, Alonso-Navarro H, Garc\u00eda-Mart\u00edn E, Santos-Garc\u00eda D, Mart\u00ednez-Valbuena I, Ag\u00fandez JAG. Alpha-Synuclein in Peripheral Tissues as a Possible Marker for Neurological Diseases and Other Medical Conditions. Biomolecules. 2023; 13: 1263.","DOI":"10.3390\/biom13081263"},{"key":"ref41","doi-asserted-by":"publisher","unstructured":"Zhang S, Cai Y, Meng C, Ding X, Huang J, Luo X, et al. The role of the microbiome in diabetes mellitus. Diabetes Research and Clinical Practice. 2021; 172: 108645.","DOI":"10.1016\/j.diabres.2020.108645"},{"key":"ref42","doi-asserted-by":"publisher","unstructured":"Cardinale A, Calabrese V, de Iure A, Picconi B. Alpha-Synuclein as a Prominent Actor in the Inflammatory Synaptopathy of Parkinson\u2019s Disease. International Journal of Molecular Sciences. 2021; 22: 6517.","DOI":"10.3390\/ijms22126517"},{"key":"ref43","doi-asserted-by":"publisher","unstructured":"Sarchione A, Marchand A, Taymans JM, Chartier-Harlin MC. Alpha-Synuclein and Lipids: The Elephant in the Room? Cells. 2021; 10: 2452.","DOI":"10.3390\/cells10092452"},{"key":"ref44","doi-asserted-by":"publisher","unstructured":"Koga S, Sekiya H, Kondru N, Ross OA, Dickson DW. Neuropathology and molecular diagnosis of Synucleinopathies. Molecular Neurodegeneration. 2021; 16: 83.","DOI":"10.1186\/s13024-021-00501-z"},{"key":"ref45","doi-asserted-by":"publisher","unstructured":"Yuan X, Tian Y, Liu C, Zhang Z. Environmental factors in Parkinson\u2019s disease: New insights into the molecular mechanisms. Toxicology Letters. 2022; 356: 1\u201310.","DOI":"10.1016\/j.toxlet.2021.12.003"},{"key":"ref46","doi-asserted-by":"publisher","unstructured":"Lindestam Arlehamn CS, Dhanwani R, Pham J, Kuan R, Frazier A, Rezende Dutra J, et al. \u03b1-Synuclein-specific T cell reactivity is associated with preclinical and early Parkinson\u2019s disease. Nature Communications. 2020; 11: 1875.","DOI":"10.1038\/s41467-020-15626-w"},{"key":"ref47","doi-asserted-by":"publisher","unstructured":"Blumenreich S, Barav OB, Jenkins BJ, Futerman AH. Lysosomal Storage Disorders Shed Light on Lysosomal Dysfunction in Parkinson\u2019s Disease. International Journal of Molecular Sciences. 2020; 21: 4966.","DOI":"10.3390\/ijms21144966"},{"key":"ref48","doi-asserted-by":"publisher","unstructured":"Poehler AM, Xiang W, Spitzer P, May VEL, Meixner H, Rockenstein E, et al. Autophagy modulates SNCA\/\u03b1-synuclein release, thereby generating a hostile microenvironment. Autophagy. 2014; 10: 2171\u20132192.","DOI":"10.4161\/auto.36436"},{"key":"ref49","doi-asserted-by":"publisher","unstructured":"Monogue B, Chen Y, Sparks H, Behbehani R, Chai A, Rajic AJ, et al. Alpha-synuclein supports type 1 interferon signalling in neurons and brain tissue. Brain: a Journal of Neurology. 2022; 145: 3622\u20133636.","DOI":"10.1093\/brain\/awac192"},{"key":"ref50","doi-asserted-by":"publisher","unstructured":"Mao X, Ou MT, Karuppagounder SS, Kam TI, Yin X, Xiong Y, et al. Pathological \u03b1-synuclein transmission initiated by binding lymphocyte-activation gene 3. Science (New York, N.Y.). 2016; 353: aah3374.","DOI":"10.1126\/science.aah3374"},{"key":"ref51","doi-asserted-by":"publisher","unstructured":"Racette BA, Gross A, Vouri SM, Camacho-Soto A, Willis AW, Searles Nielsen S. Immunosuppressants and risk of Parkinson disease. Annals of Clinical and Translational Neurology. 2018; 5: 870\u2013875.","DOI":"10.1002\/acn3.580"},{"key":"ref52","doi-asserted-by":"publisher","unstructured":"Vilela C, Ara\u00fajo B, Soares-Guedes C, Caridade-Silva R, Martins-Macedo J, Teixeira C, et al. From the Gut to the Brain: Is Microbiota a New Paradigm in Parkinson\u2019s Disease Treatment? Cells. 2024; 13: 770.","DOI":"10.3390\/cells13090770"},{"key":"ref53","doi-asserted-by":"publisher","unstructured":"Sampson TR, Challis C, Jain N, Moiseyenko A, Ladinsky MS, Shastri GG, et al. A gut bacterial amyloid promotes \u03b1-synuclein aggregation and motor impairment in mice. eLife. 2020; 9: e53111.","DOI":"10.7554\/eLife.53111"},{"key":"ref54","doi-asserted-by":"publisher","unstructured":"Xiang J, Tang J, Kang F, Ye J, Cui Y, Zhang Z, et al. Gut-induced alpha-Synuclein and Tau propagation initiate Parkinson\u2019s and Alzheimer\u2019s disease co-pathology and behavior impairments. Neuron. 2024; 112: 3585\u20133601.e5.","DOI":"10.1016\/j.neuron.2024.08.003"},{"key":"ref55","doi-asserted-by":"publisher","unstructured":"Borghammer P, Horsager J, Andersen K, Van Den Berge N, Raunio A, Murayama S, et al. Neuropathological evidence of body-first vs. brain-first Lewy body disease. Neurobiology of Disease. 2021; 161: 105557.","DOI":"10.1016\/j.nbd.2021.105557"},{"key":"ref56","doi-asserted-by":"publisher","unstructured":"Borghammer P, Van Den Berge N. Brain-First versus Gut-First Parkinson\u2019s Disease: A Hypothesis. Journal of Parkinson\u2019s Disease. 2019; 9: S281\u2013S295.","DOI":"10.3233\/JPD-191721"},{"key":"ref57","doi-asserted-by":"publisher","unstructured":"Kim S, Kwon SH, Kam TI, Panicker N, Karuppagounder SS, Lee S, et al. Transneuronal Propagation of Pathologic \u03b1-Synuclein from the Gut to the Brain Models Parkinson\u2019s Disease. Neuron. 2019; 103: 627\u2013641.e7.","DOI":"10.1016\/j.neuron.2019.05.035"},{"key":"ref58","doi-asserted-by":"publisher","unstructured":"Wakabayashi K. Where and how alpha-synuclein pathology spreads in Parkinson\u2019s disease. Neuropathology: Official Journal of the Japanese Society of Neuropathology. 2020; 40: 415\u2013425.","DOI":"10.1111\/neup.12691"},{"key":"ref59","doi-asserted-by":"publisher","unstructured":"Sawamura M, Onoe H, Tsukada H, Isa K, Yamakado H, Okuda S, et al. Lewy Body Disease Primate Model with \u03b1-Synuclein Propagation from the Olfactory Bulb. Movement Disorders: Official Journal of the Movement Disorder Society. 2022; 37: 2033\u20132044.","DOI":"10.1002\/mds.29161"},{"key":"ref60","doi-asserted-by":"publisher","unstructured":"Stefani A, Iranzo A, Holzknecht E, Perra D, Bongianni M, Gaig C, et al. Alpha-synuclein seeds in olfactory mucosa of patients with isolated REM sleep behaviour disorder. Brain: a Journal of Neurology. 2021; 144: 1118\u20131126.","DOI":"10.1093\/brain\/awab005"},{"key":"ref61","doi-asserted-by":"publisher","unstructured":"Wanyi Z, Jiao Y, Wen H, Bin X, Xuefei W, Lan J, et al. Bidirectional communication of the gut-brain axis: new findings in Parkinson\u2019s disease and inflammatory bowel disease. Frontiers in Neurology. 2024; 15: 1407241.","DOI":"10.3389\/fneur.2024.1407241"},{"key":"ref62","doi-asserted-by":"publisher","unstructured":"Sheng L, Stewart T, Yang D, Thorland E, Soltys D, Aro P, et al. Erythrocytic \u03b1-synuclein contained in microvesicles regulates astrocytic glutamate homeostasis: a new perspective on Parkinson\u2019s disease pathogenesis. Acta Neuropathologica Communications. 2020; 8: 102.","DOI":"10.1186\/s40478-020-00983-w"},{"key":"ref63","doi-asserted-by":"publisher","unstructured":"McFarthing K, Buff S, Rafaloff G, Pitzer K, Fiske B, Navangul A, et al. Parkinson\u2019s Disease Drug Therapies in the Clinical Trial Pipeline: 2024 Update. Journal of Parkinson\u2019s Disease. 2024; 14: 899\u2013912.","DOI":"10.3233\/JPD-240272"},{"key":"ref64","doi-asserted-by":"publisher","unstructured":"Smit JW, Basile P, Prato MK, Detalle L, Mathy FX, Schmidt A, et al. Phase 1\/1b Studies of UCB0599, an Oral Inhibitor of \u03b1-Synuclein Misfolding, Including a Randomized Study in Parkinson\u2019s Disease. Movement Disorders: Official Journal of the Movement Disorder Society. 2022; 37: 2045\u20132056.","DOI":"10.1002\/mds.29170"},{"key":"ref65","doi-asserted-by":"publisher","unstructured":"Wagner J, Ryazanov S, Leonov A, Levin J, Shi S, Schmidt F, et al. Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson\u2019s disease. Acta Neuropathologica. 2013; 125: 795\u2013813.","DOI":"10.1007\/s00401-013-1114-9"},{"key":"ref66","doi-asserted-by":"publisher","unstructured":"Pagano G, Monnet A, Reyes A, Ribba B, Svoboda H, Kustermann T, et al. Sustained effect of prasinezumab on Parkinson\u2019s disease motor progression in the open-label extension of the PASADENA trial. Nature Medicine. 2024; 30: 3669\u20133675.","DOI":"10.1038\/s41591-024-03270-6"},{"key":"ref67","doi-asserted-by":"publisher","unstructured":"Fang C, Hernandez P, Liow K, Damiano E, Zetterberg H, Blennow K, et al. Buntanetap, a Novel Translational Inhibitor of Multiple Neurotoxic Proteins, Proves to Be Safe and Promising in Both Alzheimer\u2019s and Parkinson\u2019s Patients. The Journal of Prevention of Alzheimer\u2019s Disease. 2023; 10: 25\u201333.","DOI":"10.14283\/jpad.2022.84"},{"key":"ref68","doi-asserted-by":"publisher","unstructured":"Meissner WG, Traon APL, Foubert-Samier A, Galabova G, Galitzky M, Kutzelnigg A, et al. A Phase 1 Randomized Trial of Specific Active \u03b1-Synuclein Immunotherapies PD01A and PD03A in Multiple System Atrophy. Movement Disorders: Official Journal of the Movement Disorder Society. 2020; 35: 1957\u20131965.","DOI":"10.1002\/mds.28218"},{"key":"ref69","doi-asserted-by":"publisher","unstructured":"Meissner WG, Remy P, Giordana C, Malt\u00eate D, Derkinderen P, Hou\u00e9to JL, et al. Trial of Lixisenatide in Early Parkinson\u2019s Disease. The New England Journal of Medicine. 2024; 390: 1176\u20131185.","DOI":"10.1056\/NEJMoa2312323"},{"key":"ref70","doi-asserted-by":"publisher","unstructured":"Neves KRT, Nobre HV, Jr, Leal LKAM, de Andrade GM, Brito GADC, Viana GSDB. Pentoxifylline Neuroprotective Effects Are Possibly Related to Its Anti-Inflammatory and TNF-Alpha Inhibitory Properties, in the 6-OHDA Model of Parkinson\u2019s Disease. Parkinson\u2019s Disease. 2015; 2015: 108179.","DOI":"10.1155\/2015\/108179"},{"key":"ref71","doi-asserted-by":"publisher","unstructured":"Khrieba MO, Hegazy SK, Mustafa W, El-Haggar SM. Repurposing celecoxib as adjuvant therapy in patients with Parkinsonian disease: a new therapeutic dawn: randomized controlled pilot study. Inflammopharmacology. 2024; 32: 3729\u20133738.","DOI":"10.1007\/s10787-024-01567-z"},{"key":"ref72","doi-asserted-by":"publisher","unstructured":"Kim Y, Ryu SH, Hyun J, Cho YS, Jung YK. TLR2 immunotherapy suppresses neuroinflammation, tau spread, and memory loss in rTg4510 mice. Brain, Behavior, and Immunity. 2024; 121: 291\u2013302.","DOI":"10.1016\/j.bbi.2024.08.002"},{"key":"ref73","doi-asserted-by":"publisher","unstructured":"Klughammer B, Piali L, Nica A, Nagel S, Bailey L, Jochum C, et al. A randomized, double-blind phase 1b study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of the NLRP3 inhibitor selnoflast in patients with moderate to severe active ulcerative colitis. Clinical and Translational Medicine. 2023; 13: e1471.","DOI":"10.1002\/ctm2.1471"},{"key":"ref74","doi-asserted-by":"publisher","unstructured":"Olson KE, Abdelmoaty MM, Namminga KL, Lu Y, Obaro H, Santamaria P, et al. An open-label multiyear study of sargramostim-treated Parkinson\u2019s disease patients examining drug safety, tolerability, and immune biomarkers from limited case numbers. Translational Neurodegeneration. 2023; 12: 26.","DOI":"10.1186\/s40035-023-00361-1"},{"key":"ref75","doi-asserted-by":"publisher","unstructured":"Olson KE, Namminga KL, Schwab AD, Thurston MJ, Lu Y, Woods A, et al. Neuroprotective Activities of Long-Acting Granulocyte-Macrophage Colony-Stimulating Factor (mPDM608) in 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Intoxicated Mice. Neurotherapeutics: the Journal of the American Society for Experimental NeuroTherapeutics. 2020; 17: 1861\u20131877.","DOI":"10.1007\/s13311-020-00877-8"},{"key":"ref76","doi-asserted-by":"publisher","unstructured":"Fasano A, Bove F, Gabrielli M, Petracca M, Zocco MA, Ragazzoni E, et al. The role of small intestinal bacterial overgrowth in Parkinson\u2019s disease. Movement Disorders: Official Journal of the Movement Disorder Society. 2013; 28: 1241\u20131249.","DOI":"10.1002\/mds.25522"},{"key":"ref77","doi-asserted-by":"publisher","unstructured":"Hong CT, Chan L, Chen KY, Lee HH, Huang LK, Yang YCSH, et al. Rifaximin Modifies Gut Microbiota and Attenuates Inflammation in Parkinson\u2019s Disease: Preclinical and Clinical Studies. Cells. 2022; 11: 3468.","DOI":"10.3390\/cells11213468"},{"key":"ref78","doi-asserted-by":"publisher","unstructured":"Pekary AE, Sattin A. Rifaximin modulates TRH and TRH-like peptide expression throughout the brain and peripheral tissues of male rats. BMC Neuroscience. 2022; 23: 9.","DOI":"10.1186\/s12868-022-00694-z"},{"key":"ref79","doi-asserted-by":"publisher","unstructured":"Bruggeman A, Vandendriessche C, Hamerlinck H, De Looze D, Tate DJ, Vuylsteke M, et al. Safety and efficacy of faecal microbiota transplantation in patients with mild to moderate Parkinson\u2019s disease (GUT-PARFECT): a double-blind, placebo-controlled, randomised, phase 2 trial. EClinicalMedicine. 2024; 71: 102563.","DOI":"10.1016\/j.eclinm.2024.102563"},{"key":"ref80","doi-asserted-by":"publisher","unstructured":"Beckers M, Coburn B, Kalia LV, Bloem BR. A Randomized Controlled Trial of Fecal Microbiota Transplantation for Parkinson\u2019s Disease: Getting it right, if not PARFECT. Journal of Parkinson\u2019s Disease. 2024; 14: 913\u2013915.","DOI":"10.3233\/JPD-249007"},{"key":"ref81","doi-asserted-by":"publisher","unstructured":"Park SY, Yang H, Kim S, Yang J, Go H, Bae H. Alpha-Synuclein-Specific Regulatory T Cells Ameliorate Parkinson\u2019s Disease Progression in Mice. International Journal of Molecular Sciences. 2023; 24: 15237.","DOI":"10.3390\/ijms242015237"},{"key":"ref82","doi-asserted-by":"publisher","unstructured":"Gao HM, Zhou H, Hong JS. NADPH oxidases: novel therapeutic targets for neurodegenerative diseases. Trends in Pharmacological Sciences. 2012; 33: 295\u2013303.","DOI":"10.1016\/j.tips.2012.03.008"}],"container-title":["Frontiers in Bioscience-Landmark"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.imrpress.com\/journal\/FBL\/30\/7\/10.31083\/FBL27178","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T06:17:16Z","timestamp":1754461036000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.imrpress.com\/journal\/FBL\/30\/7\/10.31083\/FBL27178"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,7]]},"references-count":82,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025]]}},"alternative-id":["S2768-6701(25)01644-2"],"URL":"https:\/\/doi.org\/10.31083\/fbl27178","relation":{},"ISSN":["2768-6701","2768-6698"],"issn-type":[{"value":"2768-6701","type":"print"},{"value":"2768-6698","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,7]]},"article-number":"27178"}}